ImmunityBio Investor Relations Material

Latest events

Status Update

ImmunityBio

Q3 2024

12 Nov, 2024

Q2 2024

11 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from ImmunityBio Inc

Access all reports
ImmunityBio, Inc. is a biotechnology company focused on developing innovative immunotherapies and cell therapies to treat cancer and infectious diseases. The company’s pipeline leverages platforms such as T-cell and natural killer (NK) cell-based therapies, along with vaccine technologies, to enhance the immune system’s ability to target and eliminate disease. The company is headquartered in Culver City, California, and its shares are listed on the NASDAQ.